Medical/Pharmaceuticals

Lunit INSIGHT CXR Excels in Lung Nodule Detection - Exceptional Performance in Head-to-Head Study published in Radiology

- Lunit's AI-powered chest X-ray analysis solution shows highest AUC of 0.93 in a recent multi-center, multi-use case, multi-vendor lung nodule detection study SEOUL, South Korea, Jan. 17, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostic...

2024-01-17 22:15 1866

Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

SUZHOU, China, and ROCKVILLE, Md., Jan. 16, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that olverembatinib (R&D Code: HQP1351) has been ...

2024-01-17 12:10 4169

WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

SHANGHAI, Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that a patent for WuXiBodyTM – a proprietary, highly flexible engineering platform that greatly enhances the deve...

2024-01-17 08:30 4073

Lunit AI Solutions to Power Samsung's X-ray Devices for Advanced Chest Screening

* Three-year supply contract: Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage to enhance lung abnormality detection in Samsung's premium X-ray devices SEOUL, South Korea, Jan. 16, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...

2024-01-16 22:04 1991

Complete Genomics and Gencove Announce agreement at Plant and Animal Genome Conference (PAG 31) to offer a bundled solution for low-pass whole genome sequencing

SAN JOSE, Calif., Jan. 16, 2024 /PRNewswire/ -- Complete Genomics , a life sciences company that provides novel, end-to-end DNA sequencing solutions, today announced a joint marketing agreement withGencove,  a pioneer of low-pass whole gen...

2024-01-16 22:00 1643

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

CHENGDU, China, Jan. 16, 2024 /PRNewswire/ -- Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that onJanuary 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody (bsAb), NWY001, at Sun Yat-Sen University Cancer Center inChina,...

2024-01-16 17:00 2004

PranaQ to Unveil Revolutionary Sleep Tech at CES 2024: Introducing TipTraQ, the AI Sleep Tracking and Improvement Solution

NEW YORK, Jan. 15, 2024 /PRNewswire/ -- PranaQ, the innovative sleep tech startup, has made waves at CES 2024 with the highly anticipated launch of its flagship product, TipTraQ. This cutting-edge device goes beyond traditional sleep monitoring, offering a comprehensive solution for diagnosing an...

2024-01-16 00:00 1669

CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection

SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that CT011, an autologous CAR T-cell product candidate against Glypic...

2024-01-15 21:50 1855

Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia

SHANGHAI, Jan. 14, 2024 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical-stage innovative biopharmaceutical company, announced recently that the company has completed a Phase Ib study, "An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgene...

2024-01-15 08:08 1733

San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus toSan Francisco. The J.P. Morgan Healthcare Conference has been successfully held here for 42 editions, becoming a hall where industry thought converges and spar...

2024-01-12 23:28 6297

Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule

JIUQUAN, China, Jan. 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI ) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that onJanuary 10, 2024,...

2024-01-12 20:30 5614

ClinChoice Acquires CSI, Expanding its Global Footprint into Southeast Asia

SHANGHAI, PHILADELPHIA and SINGAPORE, Jan. 11, 2024 /PRNewswire/ -- ClinChoice, a leading global Contract Research Organization (CRO), today announced expanding its global footprint with the acquisition of CSI Medical Research (CSI). CSI is a regional clinical CRO with professional staff and part...

2024-01-12 11:00 2881

United Imaging Intelligence Highlights Dedications to Advancing Intelligent Healthcare at RSNA Conference 2023

BOSTON, Jan. 11, 2024 /PRNewswire/ -- The Radiological Society of North America (RSNA) has concluded its annual meeting inChicago, IL, serving as a platform for revolutionary advancements in the field of radiology. United Imaging Intelligence (UII), an innovative subsidiary of United Imaging Grou...

2024-01-11 22:00 1467

GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia

SHANGHAI, Jan. 11, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, announced that U.S. Food and Drug Administration (FDA) has recently granted another two designations for SLS009 (GFH009). GFH009 (hig...

2024-01-11 19:00 1849

CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference

SAN FRANCISCO, Jan. 11, 2024 /PRNewswire/ -- The 42nd J.P. Morgan Annual Healthcare Conference("JPMHC")2024 is taking place onJanuary 8-11 at San Fracisco,USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, Kelun-Biotech) senior management team participated in the conferen...

2024-01-11 17:55 1871

SyntheticGestalt and Enamine to Collaborate on the Creation of AI-Based Model to Facilitate Drug Discovery

SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates. This model will utilize 38 billion compounds from Enamine REAL database as a dataset for pre-training. TOKYO and KYIV, Ukraine, Jan. 11, 2024 /PRNewswire/ -- SyntheticGestalt, a research and ...

2024-01-11 16:00 1569

Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a commercial stage global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that Dr.Dajun Yang, the company's ...

2024-01-11 11:53 4630

Robooter Showcases Innovative Power Wheelchair X40 at CES 2024

LAS VEGAS, Jan. 10, 2024 /PRNewswire/ -- Robooter, a leading autonomous mobility device manufacturer renowned for its robotic technology supporting the elderly and disabled, is proud to present the innovative power wheelchair X40 and offer a new space and mobility solution through its partners at...

2024-01-11 01:00 1388

New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted orphan drug designation by FDA

HONG KONG, Jan. 10, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine Drug Development  of Hong Kong Baptist University (HKBU) has developed a new drug using effective components of a Chinese herbal medicine, Chaenomelis Fructus, for the treatment of the rare...

2024-01-10 16:50 1808

LOTTE BIOLOGICS Announces Songdo Bio Plant Development Plan at JPM Healthcare Conference 2024

* Richard Lee, CEO of LOTTE BIOLOGICS, delivers a keynote speech at the JPM Healthcare Conference for the second consecutive year * Unveils company's bio plant development plan in Songdo to meet clients' needs SEOUL, South Korea, Jan. 9, 2024 /PRNewswire/ -- LOTTE BIOLOGICS (CEO Richard Lee) ...

2024-01-10 08:55 1496
1 ... 42434445464748 ... 214

Week's Top Stories